Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs-Reference-Cited by-同舟云学术

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs

Published:2021-09-27 Issue:19 Volume:64 Page:14498-14512
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Johannes Jeffrey W.¹^ORCID,Balazs Amber¹,Barratt Derek²,Bista Michal²,Chuba Matthew D.¹,Cosulich Sabina³,Critchlow Susan E.⁴,Degorce Sébastien L.¹,Di Fruscia Paolo²^ORCID,Edmondson Scott D.¹,Embrey Kevin²,Fawell Stephen⁵,Ghosh Avipsa¹^ORCID,Gill Sonja J.⁶,Gunnarsson Anders⁷,Hande Sudhir M.¹,Heightman Tom D.⁸,Hemsley Paul²,Illuzzi Giuditta⁴,Lane Jordan²,Larner Carrie⁶,Leo Elisabetta⁴,Liu Lina⁹,Madin Andrew²,Martin Scott¹⁰,McWilliams Lisa²,O’Connor Mark J.⁴,Orme Jonathan P.²,Pachl Fiona¹¹,Packer Martin J.¹²,Pei Xiaohui⁹,Pike Andrew¹⁰,Schimpl Marianne²^ORCID,She Hongyao⁹,Staniszewska Anna D.⁴,Talbot Verity²,Underwood Elizabeth²,Varnes Jeffrey G.¹,Xue Lin⁹,Yao Tieguang⁹,Zhang Ke⁹,Zhang Andrew X.¹¹^ORCID,Zheng Xiaolan¹

Affiliation:

1. Chemistry, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States

2. Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 OWG, U.K.

3. Oncology Projects, Oncology R&D, AstraZeneca, Cambridge CB4 OWG, U.K.

4. Bioscience, Oncology R&D, AstraZeneca, Cambridge CB4 OWG, U.K.

5. Oncology Discovery, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States

6. Oncology Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB4 OWG, U.K.

7. Discovery Sciences, R&D Gothenburg, AstraZeneca, KJ2, Pepparedsleden 1, SE-431 83 Mölndal, Sweden

8. Chemistry, Oncology R&D, AstraZeneca, Cambridge CB4 OWG, U.K.

9. Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China

10. DMPK, Oncology R&D, AstraZeneca, Cambridge CB4 OWG, U.K.

11. Discovery Sciences, R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States

12. Computational Chemistry, Oncology R&D, AstraZeneca, Cambridge CB4 OWG, U.K.

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c01012

Reference47 articles.

1. PARP inhibitors: Synthetic lethality in the clinic

2. PARP inhibitors: the race is on

3. Synthetic lethality and cancer

4. Genetic Interactions in Cancer Progression and Treatment

5. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expanding the potential of pyridine scaffold for targeted therapy of cancer: Biological activity, molecular insights, and structure-activity relationship;Journal of Molecular Structure;2025-02

2. Structure-based approaches in synthetic lethality strategies;Current Opinion in Structural Biology;2024-10

3. Synthesis and In Silico Evaluation of Piperazine-Substituted 2,3-Dichloro-5,8-dihydroxy-1,4-naphthoquinone Derivatives as Potential PARP-1 Inhibitors;ACS Omega;2024-09-10

4. The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models;Genome Medicine;2024-08-26

5. The recent advance and prospect of poly(ADP‐ribose) polymerase inhibitors for the treatment of cancer;Medicinal Research Reviews;2024-08-24